|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
IL152771A0
(en)
*
|
2000-06-26 |
2003-06-24 |
Pfizer Prod Inc |
PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
|
|
PY0228255A
(es)
|
2001-12-06 |
2004-06-01 |
Pfizer Prod Inc |
Compuestos cristalinos novedosos
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
ES2445208T3
(es)
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
DE60322544D1
(de)
*
|
2002-08-27 |
2008-09-11 |
Merck Patent Gmbh |
Glycinamid-derivate als raf-kinase-hemmer
|
|
NZ539901A
(en)
|
2002-11-26 |
2007-09-28 |
Pfizer Prod Inc |
Method of treatment of transplant rejection
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
AU2005237254B2
(en)
*
|
2004-05-03 |
2010-02-04 |
Novartis Ag |
Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
|
|
EP1768982A2
(en)
|
2004-06-29 |
2007-04-04 |
Amgen Inc. |
Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
|
|
BRPI0514094A
(pt)
|
2004-08-02 |
2008-05-27 |
Osi Pharm Inc |
composto, composição, e, método de tratamento de distúrbio hiperproliferativo
|
|
RU2007123675A
(ru)
*
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
Комбинации ингибиторов jak
|
|
AR054416A1
(es)
*
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2007007919A2
(en)
|
2005-07-14 |
2007-01-18 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
EP2251341A1
(en)
|
2005-07-14 |
2010-11-17 |
Astellas Pharma Inc. |
Heterocyclic Janus kinase 3 inhibitors
|
|
BRPI0613876A2
(pt)
*
|
2005-07-29 |
2011-02-15 |
Pfizer Prod Inc |
derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese
|
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
US8541426B2
(en)
*
|
2007-07-11 |
2013-09-24 |
Pfizer Inc. |
Pharmaceutical compositions and methods of treating dry eye disorders
|
|
US8309566B2
(en)
|
2008-02-15 |
2012-11-13 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
MX2010011463A
(es)
|
2008-04-16 |
2011-06-03 |
Portola Pharm Inc |
2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
|
|
NZ588830A
(en)
|
2008-04-22 |
2012-11-30 |
Portola Pharm Inc |
Inhibitors of protein kinases
|
|
US20110165183A1
(en)
*
|
2008-08-01 |
2011-07-07 |
Biocryst Pharmaceuticals, Inc. |
Piperidine derivatives as jak3 inhibitors
|
|
JP4884570B2
(ja)
|
2008-08-20 |
2012-02-29 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジン化合物
|
|
CA2752150A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
EP2421867B1
(en)
*
|
2009-04-20 |
2015-09-02 |
Auspex Pharmaceuticals, Llc |
Piperidine inhibitors of janus kinase 3
|
|
JP5775070B2
(ja)
|
2009-05-22 |
2015-09-09 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
|
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
EP2475667A1
(en)
*
|
2009-09-10 |
2012-07-18 |
F. Hoffmann-La Roche AG |
Inhibitors of jak
|
|
KR101921850B1
(ko)
|
2009-10-09 |
2018-11-23 |
인사이트 홀딩스 코포레이션 |
3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
|
|
CA2776028C
(en)
|
2009-10-15 |
2015-12-01 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
ES2461967T3
(es)
|
2009-12-18 |
2014-05-21 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
EP2523957A1
(en)
*
|
2010-01-12 |
2012-11-21 |
F. Hoffmann-La Roche AG |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
JP2013518882A
(ja)
|
2010-02-05 |
2013-05-23 |
ファイザー・インク |
ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
|
|
PT3354652T
(pt)
|
2010-03-10 |
2020-07-20 |
Incyte Holdings Corp |
Derivados de piperidin-4-ilazetidina como inibidores de jak1
|
|
RS54824B1
(sr)
|
2010-05-21 |
2016-10-31 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
EP2481397A1
(en)
|
2011-01-27 |
2012-08-01 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising tasocitinib
|
|
EP2481411A1
(en)
|
2011-01-27 |
2012-08-01 |
Ratiopharm GmbH |
Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
|
|
CA2827673C
(en)
|
2011-02-18 |
2020-10-27 |
Novartis Pharma Ag |
Mtor/jak inhibitor combination therapy
|
|
EP2691395B1
(en)
|
2011-03-28 |
2017-08-30 |
ratiopharm GmbH |
Processes for preparing tofacitinib salts
|
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
|
RU2013144975A
(ru)
*
|
2011-04-08 |
2015-05-20 |
Пфайзер Инк. |
Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
|
|
EP2524688B1
(en)
|
2011-05-11 |
2013-05-01 |
ratiopharm GmbH |
Composition for modified release comprising ranolazine
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
CA3094793A1
(en)
|
2011-11-23 |
2013-05-30 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
|
EP4556010A3
(en)
*
|
2011-11-30 |
2025-07-23 |
Emory University |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
|
US10821111B2
(en)
|
2011-11-30 |
2020-11-03 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
WO2013090490A1
(en)
|
2011-12-15 |
2013-06-20 |
Ratiopharm Gmbh |
Tofacitinib salts
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
WO2014016338A1
(en)
|
2012-07-25 |
2014-01-30 |
Lek Pharmaceuticals D.D. |
New synthetic route for the preparation of 3-amino-piperidine compounds
|
|
US9676756B2
(en)
|
2012-10-08 |
2017-06-13 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
CN113384546A
(zh)
|
2012-11-15 |
2021-09-14 |
因赛特公司 |
鲁索利替尼的缓释剂型
|
|
CN104955803B
(zh)
*
|
2012-11-30 |
2017-11-28 |
斯洛文尼亚莱柯制药股份有限公司 |
通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
|
|
US9481679B2
(en)
|
2012-12-17 |
2016-11-01 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of tofacitinib and intermediates thereof
|
|
WO2014102826A1
(en)
|
2012-12-28 |
2014-07-03 |
Glenmark Pharmaceuticals Limited; |
The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
|
|
CU24275B1
(es)
|
2013-02-22 |
2017-10-05 |
Pfizer |
Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
|
|
WO2014138168A1
(en)
|
2013-03-06 |
2014-09-12 |
Incyte Corporation |
Processes and intermediates for making a jak inhibitor
|
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
|
US20140343034A1
(en)
|
2013-04-25 |
2014-11-20 |
Japan Tobacco Inc. |
Skin barrier function improving agent
|
|
WO2014174073A1
(en)
|
2013-04-26 |
2014-10-30 |
Sandoz Ag |
Sustained release formulations of tofacitinib
|
|
SG10201801069QA
(en)
|
2013-08-07 |
2018-03-28 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
CN104513248B
(zh)
*
|
2013-09-30 |
2019-05-24 |
重庆医药工业研究院有限责任公司 |
一种托法替尼中间体的纯化方法
|
|
MX368464B
(es)
|
2013-12-05 |
2019-10-02 |
Pfizer |
Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
|
|
SI3539965T1
(sl)
|
2013-12-09 |
2021-07-30 |
Unichem Laboratories Limited |
Izboljšan postopek za pripravo (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamina
|
|
US9260438B2
(en)
|
2014-02-06 |
2016-02-16 |
Apotex Inc. |
Solid forms of tofacitinib salts
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
EP3180344B1
(en)
|
2014-08-12 |
2019-09-18 |
Pfizer Inc |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
EP3248980B1
(en)
*
|
2015-01-20 |
2023-09-06 |
Wuxi Fortune Pharmaceutical Co., Ltd |
Jak inhibitor
|
|
BR112017001516B1
(pt)
|
2015-02-17 |
2023-10-31 |
Amorepacific Corporation |
Método de ressolubilização quiral, estereoisômero, método para preparar um composto, composto, composição, e kit de ressolubilização quiral
|
|
CN104761556B
(zh)
*
|
2015-03-21 |
2017-06-23 |
河北国龙制药有限公司 |
托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
|
|
EP3078665A1
(en)
|
2015-04-10 |
2016-10-12 |
OLON S.p.A. |
Efficient method for the preparation of tofacitinib citrate
|
|
ES2734048T3
(es)
|
2015-04-29 |
2019-12-04 |
Wuxi Fortune Pharmaceutical Co Ltd |
Inhibidores de Janus cinasas (JAK)
|
|
US10703756B2
(en)
|
2015-05-01 |
2020-07-07 |
Pfizer Inc. |
Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
|
|
ES2822748T3
(es)
|
2015-05-29 |
2021-05-04 |
Wuxi Fortune Pharmaceutical Co Ltd |
Inhibidor de cinasa Janus
|
|
US10034882B2
(en)
*
|
2015-07-27 |
2018-07-31 |
Unichem Laboratories Limited |
Tofacitinib orally disintegrating tablets
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
CN108472298B
(zh)
|
2015-11-24 |
2021-04-20 |
深圳阿拉丁医疗科技有限公司 |
选择性激酶抑制剂
|
|
CN105348287A
(zh)
*
|
2015-11-30 |
2016-02-24 |
宁波立华制药有限公司 |
一种枸橼酸托法替布的新型合成工艺
|
|
KR102565407B1
(ko)
*
|
2016-01-04 |
2023-08-10 |
(주)아모레퍼시픽 |
극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
|
|
WO2017125417A1
(en)
|
2016-01-18 |
2017-07-27 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Tofacitinib as vaccination immune modulator
|
|
RU2714206C1
(ru)
|
2016-06-30 |
2020-02-13 |
Даевунг Фармасьютикал Ко., Лтд. |
Пиразолопиримидиновые производные в качестве ингибитора киназы
|
|
CN106831538B
(zh)
*
|
2017-01-22 |
2019-06-25 |
苏州楚凯药业有限公司 |
托法替尼中间体的制备方法
|
|
KR102398659B1
(ko)
|
2017-03-17 |
2022-05-16 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 피롤로트리아진 유도체
|
|
CN107602569A
(zh)
*
|
2017-10-23 |
2018-01-19 |
上海博悦生物科技有限公司 |
一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
|
|
KR102078805B1
(ko)
|
2017-11-30 |
2020-02-19 |
보령제약 주식회사 |
토파시티닙을 포함하는 약제학적 조성물
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
KR102577241B1
(ko)
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
|
|
IL275207B
(en)
|
2017-12-28 |
2022-09-01 |
Daewoong Pharmaceutical Co Ltd |
An oxy-fluoropiperidine derivative as a kinase inhibitor
|
|
KR102577242B1
(ko)
*
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
|
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
|
US10960006B2
(en)
*
|
2018-01-31 |
2021-03-30 |
Twi Pharmaceuticals, Inc. |
Topical formulations comprising tofacitinib
|
|
US12161748B2
(en)
|
2018-01-31 |
2024-12-10 |
Twi Biotechnology, Inc. |
Topical formulations comprising tofacitinib
|
|
MD3773593T2
(ro)
|
2018-03-30 |
2024-10-31 |
Incyte Corp |
Tratament hidradenitei supurative utilizând inhibitori ai JAK
|
|
KR102131107B1
(ko)
*
|
2019-01-15 |
2020-07-07 |
주식회사 다산제약 |
3-아미노-피페리딘 화합물의 신규한 제조 방법
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020172714A1
(en)
|
2019-02-27 |
2020-09-03 |
Samson Clinical Pty Ltd |
Treatment of autoimmune disease
|
|
US12269830B2
(en)
|
2019-03-13 |
2025-04-08 |
Intas Pharmaceuticals Ltd. |
Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
|
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
|
WO2020204647A1
(en)
*
|
2019-04-05 |
2020-10-08 |
Yuhan Corporation |
Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
|
|
CN115348858A
(zh)
|
2019-11-08 |
2022-11-15 |
凯奇生物公司 |
使用离子液体的托法替尼表面递送
|
|
WO2021094953A1
(en)
|
2019-11-14 |
2021-05-20 |
Pfizer Inc. |
1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
|
|
CN114728963B
(zh)
|
2019-11-25 |
2023-10-31 |
株式会社大熊制药 |
新型三唑吡啶衍生物和包括其的药物组合物
|
|
MX2022012135A
(es)
|
2020-04-04 |
2023-01-18 |
Pfizer |
Métodos para tratar la enfermedad de coronavirus de 2019.
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
EP4308568A1
(en)
*
|
2021-03-15 |
2024-01-24 |
Chiesi Farmaceutici S.p.A. |
Heterocyclic derivatives as janus kinase inhibitors
|
|
CN113549075B
(zh)
*
|
2021-06-23 |
2025-09-23 |
合肥华方医药科技有限公司 |
一种枸橼酸托法替布非对映异构体杂质的合成方法
|
|
EP4180042A1
(en)
|
2021-11-15 |
2023-05-17 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising micronized tofacitinib
|